ALNA - Allena Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.38
-0.29 (-2.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.67
Open11.63
Bid10.62 x 1400
Ask16.80 x 800
Day's Range11.22 - 11.71
52 Week Range6.13 - 17.56
Volume41,487
Avg. Volume126,676
Market Cap235.516M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.10
Trade prices are not sourced from all markets
  • Allena Pharmaceuticals (ALNA) Enters Oversold Territory
    Zacks3 days ago

    Allena Pharmaceuticals (ALNA) Enters Oversold Territory

    Allena Pharmaceuticals, Inc. (ALNA) has been on a bit of a cold streak lately

  • GlobeNewswire26 days ago

    Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the completion of an animal proof-of-concept study supporting the selection of ALLN-346 as its lead product candidate for the treatment of hyperuricemia in patients with gout and associated chronic kidney disease (CKD).

  • GlobeNewswirelast month

    Allena Pharmaceuticals Appoints Andrew A. F. Hack, M.D., Ph.D., to its Board of Directors

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Andrew A. F. Hack, M.D., Ph.D., to its Board of Directors. Dr. Hack will serve as Chair of the Audit Committee. “Andrew is a proven leader in the biotechnology industry, with a valuable array of experiences in financial, strategic and advisory roles across the sector,” said Alexey Margolin, Ph.D., Chief Executive Officer of Allena Pharmaceuticals.

  • GlobeNewswire2 months ago

    Allena Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Alexey Margolin, Ph.D., Allena’s Chief Executive Officer, will present a company overview at the Jefferies 2018 Healthcare Conference on Wednesday, June 6, 2018 at 2:00 p.m. ET in New York, NY. A live audio webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders.

  • GlobeNewswire2 months ago

    Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

    --Initiated Phase 3 Study URIROX-1™ and Phase 2 Study 206 for ALLN-177 in Patients with Severe Hyperoxaluria--. --Reiterates Guidance for Key Objectives Across Portfolio--. NEWTON, Mass., May 08, 2018-- ...

  • Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?
    Simply Wall St.3 months ago

    Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?

    The most recent earnings announcement Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level – great news for investorsRead More...

  • Allena Pharmaceuticals (ALNA) Enters Overbought Territory
    Zacks3 months ago

    Allena Pharmaceuticals (ALNA) Enters Overbought Territory

    Allena Pharmaceuticals, Inc. (ALNA) has moved higher as of late, but there could definitely be trouble on the horizon for this company

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool4 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these hot stocks keep the momentum going?

  • Who Are The Top Investors In Allena Pharmaceuticals Inc (NASDAQ:ALNA)?
    Simply Wall St.5 months ago

    Who Are The Top Investors In Allena Pharmaceuticals Inc (NASDAQ:ALNA)?

    In this article, I’m going to take a look at Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • GuruFocus.com5 months ago

    Pharmstandard International S.A. Buys Allena Pharmaceuticals Inc

    Investment company Pharmstandard International S.A. buys Allena Pharmaceuticals Inc during the 3-months ended 2017-12-31, according to the most recent filings of the investment company, Pharmstandard International ...

  • What Is The Future Prospect For Healthcare And Allena Pharmaceuticals Inc (ALNA)?
    Simply Wall St.8 months ago

    What Is The Future Prospect For Healthcare And Allena Pharmaceuticals Inc (ALNA)?

    Allena Pharmaceuticals Inc (NASDAQ:ALNA), a USD$261.28M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...

  • Allena Pharmaceuticals Inc (ALNA): Time For A Financial Health Check
    Simply Wall St.8 months ago

    Allena Pharmaceuticals Inc (ALNA): Time For A Financial Health Check

    Investors are always looking for growth in small-cap stocks like Allena Pharmaceuticals Inc (NASDAQ:ALNA), with a market cap of USD $238.80M. However, an important fact which most ignore is: howRead More...